High levels of gadolinium deposition in the skin of a patient with normal renal function

Investigative Radiology

Volumn 51, Issue 5, 2016, Pages 280-289

  Roberts, Donna R ^a   Lindhorst, Scott M ^a   Welsh, Cynthia T ^a   Maravilla, Kenneth R ^b   Herring, Mary N ^a   Braun, K Adam ^a   Thiers, Bruce H ^a   Davis, W Clay ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

Gadolinium retention; Normal renal function; Skin

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; CONTRAST MEDIUM;

ACUTE CHOLECYSTITIS; ADULT; ARTICLE; BRAIN SCINTISCANNING; BRAIN TUMOR; CANCER CHEMOTHERAPY; CASE REPORT; CHOLECYSTECTOMY; COMMON BILE DUCT STONE; CONNECTIVE TISSUE; DRUG RETENTION; FATIGUE; GLIOBLASTOMA; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IMMUNOREACTIVITY; JOINT CONTRACTURE; KIDNEY FUNCTION; MASS SPECTROMETRY; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION EXPOSURE; SIZE EXCLUSION CHROMATOGRAPHY; SKIN BIOPSY; YOUNG ADULT; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; KIDNEY; METABOLISM; PROCEDURES; SKIN;

ADULT; BRAIN NEOPLASMS; CONTRAST MEDIA; GADOLINIUM; GLIOBLASTOMA; HUMANS; KIDNEY; MAGNETIC RESONANCE IMAGING; SKIN; YOUNG ADULT;

EID: 84960193713     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000266     Document Type: Article

References (25)

1. Idee JM, Fretellier N, Robic C, et al. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update. Crit Rev Toxicol. 2014; 44:895-913.
2. Runge VM, Ai T, Hao D, et al. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol. 2011; 46:807-816.
3. PortM, Idée JM,Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
4. Boyd AS, Sanyal S, Abraham JL. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. J Am Acad Dermatol. 2008;59:356-358.
5. Christensen KN, Lee CU, HanleyMM, et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2011;64:91-96.
6. HighWA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56: 21-26.
7. HighWA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56: 710-712.
8. HighWA, Ranville JF, BrownM, et al. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol. 2010;62:38-44.
9. Khurana A, Greene JF Jr, HighWA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol. 2008;59:218-224.
10. Birka M, Wentker KS, Lusmoller E, et al. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem. 2015;87:3321-3328.
11. Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patientswith normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685-690.
12. Kanda T, Fukusato T, MatsudaM, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228-232.
13. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weightedMR images: relationshipwith increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834-841.
14. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275:803-809.
15. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782.
16. Quattrocchi CC,Mallio CA, ErranteY, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470-472.
17. Radbruch A,Weberling LD, Kieslich PJ, et al. Gadoliniumretention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783-791.
18. Radbruch A,Weberling LD, Kieslich PJ, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805-810.
19. RungeVM. Macrocyclic versus linear gadoliniumchelates. Invest Radiol. 2015;50:811.
20. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015;50:743-748.
21. Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65: 1095.e7-1106. e7.
22. EMEA. European Medicines Agency makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents. 2009. Doc. ref. EMEA/CHMP/739818/2009. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2009/11/news-detail-000408.jsp&mid=WC0b01ac058004d5c1. Accessed October 12, 2015.
23. FDA. FDA drug safety communication: new warnings for using gadoliniumbased contrast agents in patients with kidney dysfunction. Safety Announcement, August 9, 2010. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed October 12, 2015.
24. Contrast Media Safety Committee of the European Society of Urogenital Radiology. ESUR Contrast Media Guidelines Version 8.1. 2012. http://www.esur.org/guidelines/.
25. ACR Committee on Drugs and ContrastMedia. ACR Manual on Contrast Media Version 10.1. 2015. http://www.acr.org/quality-safety/resources/contrast-manual.